13F Holdings
中文EN

CYDY CytoDyn Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1175680 · Fiscal year ends 05/31

Financial factors as of 2026-08-31 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-171.6%
TTM EPS YoY-100.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-351.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets614.7%
Debt / equity—
Current ratio0.38x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.39x
Accruals ratio-212.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-05-31FY20252025-05-31FY20242024-05-31FY20232023-05-31FY20222022-05-31
Income statement
Revenue———$0$266,000
Cost of revenue————$53,000
Gross profit————$213,000
R&D expense——$7.24M$2.63M$27.04M
SG&A expense$7.45M$7.26M$10.82M$17.14M$44.30M
Operating income-$38.58M$9.66M-$18.06M-$40.58M-$145.40M
Interest expense——$31.78M$39.25M$65.42M
Pretax income-$42.70M$3.75M-$49.84M-$79.82M-$210.82M
Income tax$0$0$0$0$0
Net income-$42.70M$3.75M-$49.84M-$79.82M-$210.82M
EBITDA-$38.56M$9.68M-$18.03M-$40.40M-$144.62M
EPS (basic)-0.030.00-0.05-0.10-0.31
EPS (diluted)-0.030.00-0.05-0.10-0.31
Weighted avg. shares (diluted)1.29B1.24B969.51M836.53M676.90M
Balance sheet
Cash & equivalents$11.85M$11.90M$9.81M$9.05M$4.23M
Inventory——$0$0—
Current assets$13.88M$17.88M$10.81M$10.80M$10.52M
PP&E, net————$73,000
Intangibles————$132,000
Total assets$13.97M$18.05M$11.14M$11.29M$29.18M
Current liabilities$53.73M$70.52M$84.18M$119.80M$123.16M
Long-term debt$38.34M$45.35M$45.02M$45.73M$42.22M
Total debt$38.34M$45.35M$45.02M$45.73M$42.22M
Total liabilities$123.69M$114.09M$127.89M$120.79M$123.58M
Shareholders' equity-$109.72M-$96.04M-$116.76M-$109.50M-$94.40M
Net debt$26.49M$33.45M$35.21M$36.68M$37.98M
Shares outstanding1.37B1.25B1.06B918.61M719.59M
Cash flow statement
Operating cash flow-$17.25M-$8.77M-$10.98M-$25.11M-$77.72M
Investing cash flow$0$0———
Financing cash flow$17.20M$10.85M$11.75M$29.93M$48.01M
Depreciation & amortization$17,000$18,000$29,000$175,000$781,000
Stock-based compensation$1.63M$1.61M$2.42M$4.28M$6.24M

Free plan shows the latest 5 periods; Pro shows all 22 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.